Portland、ORにおける膵臓がんの臨床試験
Portlandとその周辺地域（約30マイル以内）の拠点で、膵臓がんに関する19件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
被験者募集中第3相
- Oregon Health and Science University, Portland
A Study of PHN-012 in Patients With Advanced Solid Tumors
被験者募集中第1相
- PHN-012-001 Site, Portland
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
被験者募集中第2/3相
- OHSU Center for Health & Healing 1, Portland
- Oregon Health and Science University, Portland
- OSHU Center for Health and Healing 2, Portland
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
被験者募集中第3相
- Investigative Site US042, Portland
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
被験者募集中第3相
- Oregon Health & Science University - OHSU Knight Cancer Institute, Portland
Pancreatic Cancer Detection Consortium (PCDC) Prospective Cohorts
被験者募集中観察研究
- Oregon Health & Science University, Portland
Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs and Associated Biomarkers
被験者募集中観察研究
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Oregon Health and Science University, Portland
- 他1件
Targeted Pathway Inhibition in Patients With Pancreatic Cancer
被験者募集中早期第1相
- OHSU Knight Cancer Institute, Portland
Use Of Indocyanine Green In Pancreas Surgery
被験者募集中観察研究
- OHSU Knight Cancer Institute, Portland
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
被験者募集中第3相
- Oregon Health and Science University, Portland
A Study of MGC026 in Participants With Advanced Solid Tumors
被験者募集中第1相
- Providence Cancer Institute, Portland
Pancreatic Cancer Early Detection Consortium
被験者募集中観察研究健康なボランティア歓迎
- Oregon Health & Science University, Portland
A Tailored, Web-based Program (COMPASS) to Improve Exercise and Dietary Changes in Stage I-III Pancreatic Cancer Patients Receiving Neoadjuvant Chemotherapy
被験者募集中
- OHSU Knight Cancer Institute, Portland
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
被験者募集中第3相
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12マイル先
OMO-103 for the Treatment of Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma
被験者募集中早期第1相
- OHSU Knight Cancer Institute, Portland
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
被験者募集中第2相
- Ohio State University-Telemedicine, Portland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
被験者募集中観察研究健康なボランティア歓迎
- Oregon Health Sciences University, Portland
LOTUS-CC: An Observational Research Study to Uncover Subtypes of Cancer Cachexia
被験者募集中観察研究
- Providence Portland Medical Center, Portland
- Providence Saint Vincent Medical Center, Portland
- Providence Willamette Falls Medical Center, Oregon City · 12マイル先
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Portland
他の都市における膵臓がんの試験
- Houston, TX61件の研究
- New York City, NY60件の研究
- Boston, MA43件の研究
- Nashville, TN39件の研究
- Los Angeles, CA35件の研究
- St. Louis, MO33件の研究
- Arlington, VA33件の研究
- Baltimore, MD31件の研究
- San Antonio, TX31件の研究
- Philadelphia, PA26件の研究
- Tampa, FL26件の研究
- Durham, NC24件の研究
Portlandにおける他の研究
- 非小細胞肺癌46件の研究
- がん（全種類）34件の研究
- 乳がん33件の研究
- 前立腺がん33件の研究
- 転移性癌29件の研究
- 大腸癌28件の研究
- 卵巣がん27件の研究
- 肺がん26件の研究
- 急性骨髄性白血病25件の研究
- 子宮内膜がん24件の研究
- 頭頸部扁平上皮癌19件の研究
- 心不全17件の研究
ClinicalTrials.govより、2026/10/06時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。